Effect of dual blockade of renin-angiotensin system on TGF beta 1 and left ventricular structure and function in hypertensive patients
- Autori: Scaglione, R.; Argano, C.; DI CHIARA, T.; Parrinello, G.; Colomba, D.; Avellone, G.; Donatelli, M.; Corrao, S.; Licata, G.
- Anno di pubblicazione: 2007
- Tipologia: Articolo in rivista
- Parole Chiave: ace-inhibitors; angiotensin II receptor blockers; left ventricular geometry and function; procollagen type I and III; transforming growth factor b1
- OA Link: http://hdl.handle.net/10447/23867
The effects of 24 weeks losartan and ramipril treatment,both alone and in combination, on left ventricular mass (LVM), circulating transforming growth factor b1(TGFb1), procollagen type I (PIP) and III (PIIIP), havebeen evaluated in hypertensive (HT) patients. A total of 57 HT with stage 1 and 2 essential hypertension were included. After 4 weeks run in, a randomized double blind, three arms, double dummy, independent trial was used. All HT patients were randomly allocated to three treatment arms consisting of losartan (50 mg/daily),ramipril (5 mg/ daily) and combined (losartan 50 mg/daily plus ramipril 5 mg/daily) for 24 weeks. TGFb1, PIP and PIIIP, LVM, LVM/h 2.7 and other echocardiographic measurements, blood urea nitrogen, creatinine and clearance and potassium were determined after run in and after 24 weeks. All groups were comparable for gender, age, body mass index, blood pressure and LVM. The prevalence of baseline left ventricular hypertrophy (LVH) was not significantly different among three groups. At the end of treatment, a significant (P<0.05) reduction in systolic blood pressure (SBP), diastolic blood pressure (DBP), mean blood pressure (MBP), TGFb1, PIP, PIIIP, LVM and LVM/h 2.7 was observed in all groups. The absolute and percent reduction in TGFb1and LVM/h2.7 were significantly higher in combined than losartan or ramipril groups and also in HT patients with LVH. No significant change in absolute and percent reduction of SBP, DBP and MBP were found. Our data indicate an additional cardioprotective effect of dual blockade of renin–angiotensin in HT patients.